GRAIL Inc. (GRAL)
| Bid | 23.33 |
| Market Cap | 835.32M |
| Revenue (ttm) | 125.59M |
| Net Income (ttm) | -2.03B |
| EPS (ttm) | -63.54 |
| PE Ratio (ttm) | -0.39 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 25.44 |
| Volume | 1,071,778 |
| Avg. Volume (20D) | 1,556,477 |
| Open | 24.88 |
| Previous Close | 23.26 |
| Day's Range | 23.80 - 25.75 |
| 52-Week Range | 12.33 - 63.99 |
| Beta | 4.93 |
About GRAL
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated ...
Analyst Forecast
According to 2 analyst ratings, the average rating for GRAL stock is "Hold." The 12-month stock price forecast is $20, which is a decrease of -19.55% from the latest price.
Stock Forecasts
2 months ago · investopedia.com
Watch These Grail Price Levels After Med Tech Company's Stock Soared 64% Last WeekGrail (GRAL) shares could remain in focus after surging to a new record high on Friday to cap off a huge week of gains amid optimism about the medical technology company's early-detection cancer scree...
2 months ago · investopedia.com
Early Cancer Detection Firm Grail Leads Nasdaq Gainers as Stock Jumps 20%Shares of Grail, Inc. (GRAL) surged 20% intraday Wednesday, putting the medical technology company above the likes of Arm Holdings (ARM) and Netflix (NFLX) to be the biggest gainer in the Nasdaq 100 i...